3:08 AM
 | 
Apr 30, 2019
 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

$82M B round to advance small molecules from proteome-wide drug discovery platform

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest.

Now flush with over $165 million in cash, Vividion Therapeutics Inc. CEO Diego Miralles said the company will be able to generate clinical proof-of-concept data for at least two programs.

Vividion is identifying small molecules against targets once deemed to be undruggable by using its screening technology to analyze every protein within the cell in combination with synthetic chemistry. The platform comprises a collection of tools developed in the lab of Ben Cravatt, a Vividion...

Read the full 506 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >